Holen Sie sich die Stockscreener-App
12.85
1.23%
-0.16
Handel nachbörslich:
13.21
0.36
+2.80%
Schlusskurs vom Vortag:
$13.01
Offen:
$13.01
24-Stunden-Volumen:
1.15M
Relative Volume:
0.89
Marktkapitalisierung:
$793.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-5.7366
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
+15.35%
1M Leistung:
+73.41%
6M Leistung:
+161.71%
1J Leistung:
+51.18%
1-Tages-Spanne:
$12.52
$13.22
1-Wochen-Bereich:
$11.26
$13.22
52-Wochen-Spanne:
$3.5001
$13.22
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie GLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
12.85 | 803.49M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionRecession Risk & Weekly High Return Forecasts - newser.com
Is it time to cut losses on Monte Rosa Therapeutics Inc.Trade Signal Summary & Expert Approved Momentum Ideas - newser.com
Is Monte Rosa Therapeutics Inc. meeting your algorithmic filter criteriaTrade Ideas & Low Risk Investment Opportunities - newser.com
Chart based exit strategy for Monte Rosa Therapeutics Inc.Market Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
Forecasting Monte Rosa Therapeutics Inc. price range with options dataMarket Movers & Safe Entry Trade Reports - newser.com
Cwm LLC Raises Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (GLUE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Monte Rosa Therapeutics, Inc. (GLUE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Monte Rosa Therapeutics (NASDAQ:GLUE) Given Sell (D+) Rating at Weiss Ratings - MarketBeat
Monte Rosa Therapeutics Hits New 52-Week High of $13.10 - Markets Mojo
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Custom watchlist performance reports with Monte Rosa Therapeutics Inc.Bull Run & Technical Entry and Exit Alerts - newser.com
What to do if you’re stuck in Monte Rosa Therapeutics Inc.July 2025 Momentum & Reliable Intraday Trade Alerts - newser.com
Visual trend scoring systems applied to Monte Rosa Therapeutics Inc.Weekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Why Monte Rosa Therapeutics Inc. stock is popular among millennialsJuly 2025 Outlook & Technical Pattern Alert System - newser.com
Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study - MSN
Monte Rosa Therapeutics Hits New 52-Week High of $12.97 - Markets Mojo
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study - MSN
What analysts say about Monte Rosa Therapeutics Inc stockDividend Reinvestment Plans & Small Investment Growth Tips - earlytimes.in
How Regulatory Changes Could Impact ICDS Limiteds BusinessRelative Strength Index (RSI) & Learn to Trade Without Fear of Loss - earlytimes.in
Working capital per share of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Published on: 2025-10-30 01:39:11 - newser.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Yahoo Finance
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Why Monte Rosa Therapeutics Inc. stock is trending among retail tradersJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - fcp.pa.gov.br
Is Monte Rosa Therapeutics Inc. stock a buy before product launches2025 Winners & Losers & Weekly Stock Performance Updates - fcp.pa.gov.br
Monte Rosa Therapeutics, Inc. Experiences Valuation Adjustment Amid Strong Performance Metrics - Markets Mojo
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):